← SynDRA
DEXRAZOXANE
SynDRA canonical compound SYN0020004 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | TOP2A | TOP2B |
|---|
| Mechanism of action | chelating agent | topoisomerase inhibitor |
|---|
| Indication | cardiomyopathy |
|---|
| Disease area | cardiology |
|---|
All known targets
Mechanisms of action (all sources)
- TOP2A INHIBITOR
- DNA topoisomerase II inhibitor
- TOP2B INHIBITOR
- topoisomerase inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- PTGS1
- ACHE
- ADORA3
- TBXA2R
- SLC6A4
- SLC6A3
- SLC6A2
- PGR
- PDE4A
- PDE3A
- OPRM1
- MAOA
- KCNH2
- HTR2B
- HTR1A
- HRH3
- HDAC6
- F2
- ESR1
- ENGASE
- DRD3
- DRD1
- CHRM2
- CHRM1
- AR
- ADRA2A
- ADRA1A
- TDP1
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Drug classes
- Cytoprotective Agent
- Antineoplastic Agents
- Cardiotonic Agents
- Cardiovascular Agents
- Enzyme Inhibitors
- Protective Agents
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- chelating agent
ATC classes
- V03A · ALL OTHER THERAPEUTIC PRODUCTS
Cross-references
Synonyms
- DEXRAZOXANE HYDROCHLORIDE
- TOTECT
- Totect
- ZINECARD
- zinecard
- savene
- totect
- dexrazoxane hydrochloride
- dexrazoxane HCl
- Dexrazoxano
- Razoxane (+)-form
- Razoxane, (s)-
- Razoxane, d-
- ADR-529
- ICRF-187
- NSC-169780
- Cardioxane
- Zinecard
- ICRF 187
- Dexrazoxanum
- Dextrorazoxane
- Dexrazoxanum [INN-Latin]
- Dexrazoxano [INN-Spanish]
- Desrazoxane
- Eucardion
- Dexrazone
- HSDB 7319
- UNII-048L81261F
- NSC169780
- dyzoxane
- BRN 5759131
- CHEBI:50223
- NSC 169780
- AK-72797
- Razoxanum
- Savene
- TopoTect
- Dexrazoxane HCl
Reported adverse events
- Alopecia
- Fatigue
- Infection
- Nausea
- Phlebitis
- Stomatitis
- Vomiting
- Dysphagia
- Erythema
- Extravasation
- Malaise
- Neurotoxicity
Look up DEXRAZOXANE in the interactive SynDRA portal →